An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

linking the pathogenesis of Crohn’s disease with this inflammation pathway. The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of ...

The global market for ustekinumab, Stelara's active ingredient ... options to patients diagnosed with ulcerative colitis, Crohn's disease, psoriasis, and psoriatic arthritis,” said Celltrion ...

Stelara (ustekinumab) was launched almost 15 years ago as a treatment for psoriasis and in the interim has picked up additional indications in psoriatic arthritis, Crohn’s disease, and ...

Vigorous protection of Stelara’s position in the immunology ... colitis and an expected approval of the therapy for Crohn’s disease. Duato also mentioned that the company views the future ...